I wanted to alert the board that the first preliminary phase 2 clinical trial results for RRx-001 dosed for CRC (randomized against the current stand of care regorafenib) were released this week at this link: http://tatcongress.org/wp-content/uploa ... Carter.pdf
I have been tracking RRx-001 pretty closely for a while. I have been attracted by its minimal side effect profile and signs that it can resensisitze tumors to chemo which had previous the patient had failed (e.g. irinotecan). Conceptually this in theory many allow a treatment pattern where you could alternate between chemo and take shorts bursts of RRx-001 during rest periods to bring back chemo efficacy to convert stage IV CRC into a chronic condition - although that paradigm still has to be clearly proven in clinical trials.
A case study has been published of 2 CRC patients from the Phase 1 trial resensitized to previous chemo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934615/
As well as a discussion on this strategy: http://www.sciencedirect.com/science/ar ... 3314000916
To my eyes, the preliminary Phase 2 data seems to be replicating what they saw in the Phase 1 trial (resensitizing multiple CRC patients to previously failed chemo), although the patient numbers are still too small to say conclusively.
Here is the link to the in-progress Phase 2 clinical trial: https://clinicaltrials.gov/ct2/show/NCT02096354
All the best,
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/2016 Colondar 2.0 ModelDK37 Science Posts List